Taken together with previous observational, genomic, and early trial data, our findings support the integration of aspirin into clinical practice for a molecularly defined subgroup of patients with ...

We have a very high response rate, very deep response rate, and very high MRD negativity rates,” said study presenter Marc S. Raab, MD.

Improvements in cause-specific and overall survival seen for those residing in rural and high-poverty communities.

Emerging therapies such as bezuclastinib and elenestinib show promise in improving disease control with potentially fewer toxicities. Other novel strategies, such as immune-based therapies, are under ...

Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.

Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.